Shire share price: first quarter results reported

on Apr 30, 2015
Updated: Oct 21, 2019

Shire Plc (LON:SHP) updated investors today with its financial results for the first quarter of 2015. Following are the highlights of the company’s statement.

Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.

**Highlights from Shire’s statement:**
Shire delivers strong revenue growth and cash generation; 20% increase in Non GAAP earnings per ADS Continued advancement toward goal of becoming a leading global biotechnology company.
April 30, 2015 – Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months to March 31, 2015.
* Strong product sales growth of 9% (13% on a CER basis) to $1.4 billion, driven by performance of VYVANSE®, CINRYZE®, FIRAZYR® and LIALDA®/MEZAVANT®.
* Non GAAP earnings per ADS up 20% (up 24% on a CER basis).
* Acquisition of NPS Pharmaceuticals, Inc. (“NPS”) completed and integration progressing according to plan.
* Commercial portfolio strengthened through the addition of GATTEX®/REVESTIVE ® and NATPARA® from NPS and the launch of VYVANSE for Binge Eating Disorder in adults.
* Pipeline progressed, with the most significant developments being PriorityReview for lifitegrast and agreement with the FDA on the regulatory path for SHP465. Shire now has its broadest and deepest pipeline in its history.
Flemming Ornskov, M.D., Shire’s Chief Executive Officer, commented:
During the first quarter, Shire continued to exemplify the characteristics of a leading biotechnology company, delivering strong revenue growth and cash generation, while materially advancing our innovative pipeline and boosting our future growth profile through the acquisition of NPS. Our continued financial performance driven by the strength of our commercial operations, focus on efficiency, and breadth of our innovative pipeline are indicators of our bright future. We remain confident in delivering Non GAAP diluted earnings per ADS growth in the mid-single digits in 2015 (high single digit growth on a CER basis).
**More to follow…**
As of 12:05 BST, Thursday, 30 April, Shire PLC share price is 5,427.50p.


Want easy-to-follow crypto, forex & stock trading signals? Make trading simple by copying our team of pro-traders. Consistent results. Sign-up today at Invezz Signals.

Learn more
Health & pharma Manufacturing Stock Market